These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Microarray analysis of Dupuytren's disease cells: the profibrogenic role of the TGF-β inducible p38 MAPK pathway. Ratkaj I; Bujak M; Jurišić D; Baus Lončar M; Bendelja K; Pavelić K; Kraljević Pavelić S Cell Physiol Biochem; 2012; 30(4):927-42. PubMed ID: 22965824 [TBL] [Abstract][Full Text] [Related]
3. Genome-wide analysis using exon arrays demonstrates an important role for expression of extra-cellular matrix, fibrotic control and tissue remodelling genes in Dupuytren's disease. Forrester HB; Temple-Smith P; Ham S; de Kretser D; Southwick G; Sprung CN PLoS One; 2013; 8(3):e59056. PubMed ID: 23554969 [TBL] [Abstract][Full Text] [Related]
5. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. Shih B; Wijeratne D; Armstrong DJ; Lindau T; Day P; Bayat A J Hand Surg Am; 2009 Jan; 34(1):124-36. PubMed ID: 19121738 [TBL] [Abstract][Full Text] [Related]
6. RNA sequencing reveals a depletion of collagen targeting microRNAs in Dupuytren's disease. Riester SM; Arsoy D; Camilleri ET; Dudakovic A; Paradise CR; Evans JM; Torres-Mora J; Rizzo M; Kloen P; Julio MK; van Wijnen AJ; Kakar S BMC Med Genomics; 2015 Oct; 8():59. PubMed ID: 26446724 [TBL] [Abstract][Full Text] [Related]
7. Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells. Vi L; Feng L; Zhu RD; Wu Y; Satish L; Gan BS; O'Gorman DB Exp Cell Res; 2009 Dec; 315(20):3574-86. PubMed ID: 19619531 [TBL] [Abstract][Full Text] [Related]
8. Expression of a novel gene, MafB, in Dupuytren's disease. Lee LC; Zhang AY; Chong AK; Pham H; Longaker MT; Chang J J Hand Surg Am; 2006 Feb; 31(2):211-8. PubMed ID: 16473681 [TBL] [Abstract][Full Text] [Related]
9. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. Rehman S; Salway F; Stanley JK; Ollier WE; Day P; Bayat A J Hand Surg Am; 2008 Mar; 33(3):359-72. PubMed ID: 18343292 [TBL] [Abstract][Full Text] [Related]
10. The effect of 5-fluorouracil on Dupuytren fibroblast proliferation and differentiation. Jemec B; Linge C; Grobbelaar AO; Smith PJ; Sanders R; McGrouther DA Chir Main; 2000 Feb; 19(1):15-22. PubMed ID: 10777424 [TBL] [Abstract][Full Text] [Related]
11. Developing an animal model of Dupuytren's disease by orthotopic transplantation of human fibroblasts into athymic rat. Satish L; Palmer B; Liu F; Papatheodorou L; Rigatti L; Baratz ME; Kathju S BMC Musculoskelet Disord; 2015 Jun; 16():138. PubMed ID: 26049932 [TBL] [Abstract][Full Text] [Related]
12. Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Verjee LS; Verhoekx JS; Chan JK; Krausgruber T; Nicolaidou V; Izadi D; Davidson D; Feldmann M; Midwood KS; Nanchahal J Proc Natl Acad Sci U S A; 2013 Mar; 110(10):E928-37. PubMed ID: 23431165 [TBL] [Abstract][Full Text] [Related]
13. Dupuytren's disease metabolite analyses reveals alterations following initial short-term fibroblast culturing. Rehman S; Xu Y; Dunn WB; Day PJ; Westerhoff HV; Goodacre R; Bayat A Mol Biosyst; 2012 Sep; 8(9):2274-88. PubMed ID: 22772395 [TBL] [Abstract][Full Text] [Related]
14. Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy. Iqbal SA; Manning C; Syed F; Kolluru V; Hayton M; Watson S; Bayat A Stem Cells Dev; 2012 Mar; 21(4):609-22. PubMed ID: 21612554 [TBL] [Abstract][Full Text] [Related]
15. Identification of histological patterns in clinically affected and unaffected palm regions in dupuytren's disease. Alfonso-Rodríguez CA; Garzón I; Garrido-Gómez J; Oliveira AC; Martín-Piedra MÁ; Scionti G; Carriel V; Hernández-Cortés P; Campos A; Alaminos M PLoS One; 2014; 9(11):e112457. PubMed ID: 25379672 [TBL] [Abstract][Full Text] [Related]
16. Dupuytren's Disease Is Mediated by Insufficient TGF-β1 Release and Degradation. Oezel L; Wohltmann M; Gondorf N; Wille J; Güven I; Windolf J; Thelen S; Jaekel C; Grotheer V Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894778 [TBL] [Abstract][Full Text] [Related]
17. Whole genome and global expression profiling of Dupuytren's disease: systematic review of current findings and future perspectives. Shih B; Watson S; Bayat A Ann Rheum Dis; 2012 Sep; 71(9):1440-7. PubMed ID: 22772327 [TBL] [Abstract][Full Text] [Related]
18. IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease. Raykha C; Crawford J; Gan BS; Fu P; Bach LA; O'Gorman DB Biochim Biophys Acta; 2013 Oct; 1832(10):1511-9. PubMed ID: 23623986 [TBL] [Abstract][Full Text] [Related]
19. First identification of resident and circulating fibrocytes in Dupuytren's disease shown to be inhibited by serum amyloid P and Xiapex. Iqbal SA; Hayton MJ; Watson JS; Szczypa P; Bayat A PLoS One; 2014; 9(6):e99967. PubMed ID: 24933153 [TBL] [Abstract][Full Text] [Related]
20. Screening of potential prodrugs on cells derived from Dupuytren's disease patients. Kraljevic Pavelic S; Bratulic S; Hock K; Jurisic D; Hranjec M; Karminski-Zamola G; Zinic B; Bujak M; Pavelic K Biomed Pharmacother; 2009 Sep; 63(8):577-85. PubMed ID: 19010640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]